Table 1.
Baseline characteristics of the IPDE population
| Characteristics | 2nd line (n = 10) | 3rd line (n = 17) | ≥4th line (n = 40) | Total (N = 67) |
|---|---|---|---|---|
| Age at informed consent (years) | ||||
| Mean (SD) | 59.6 (13.57) | 64.6 (8.66) | 59.9 (10.03) | 61.1 (10.35) |
| Median | 60.0 | 64.0 | 59.0 | 60.0 |
| Range | 32, 80 | 51, 82 | 39, 87 | 32, 87 |
| Age category (years) | ||||
| ≥18–≤64 | 6 (60) | 9 (53) | 30 (75) | 45 (67) |
| ≥65 | 4 (40) | 8 (47) | 10 (25) | 22 (33) |
| Sex | ||||
| Male | 3 (30) | 10 (59) | 30 (75) | 43 (64) |
| Female | 7 (70) | 7 (41) | 10 (25) | 24 (36) |
| ECOG status | ||||
| 0 | 8 (80) | 9 (53) | 19 (48) | 36 (54) |
| 1 | 2 (20) | 8 (47) | 20 (50) | 30 (45) |
| 2 | 0 | 0 | 1 (3) | 1 (2) |
| Primary Mutations | ||||
| KIT exon 11 | 8 (80) | 12 (71) | 28 (70) | 48 (72) |
| KIT exon 9 | 1 (10) | 5 (29) | 8 (20) | 14 (21) |
| KIT other exons | 0 | 0 | 2 (5) | 2 (3) |
| PDGFRA (exon 18, non-D842V) | 1 (10) | 0 | 2 (5) | 3 (5) |
Data presented as n (%) unless otherwise indicated. Percentages were rounded to the nearest whole number.
ECOG, Eastern Cooperative Oncology Group; IPDE, intrapatient dose escalation; PDGFRA, platelet-derived growth factor receptor alpha; SD, standard deviation.